Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone800-556-0311
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90.86 million
Profitability
Miscellaneous
Employees216
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Vericel (NASDAQ:VCEL) Frequently Asked Questions
What is Vericel's stock symbol?
Vericel trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) issued its quarterly earnings results on Tuesday, February, 26th. The biotechnology company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.06. The biotechnology company had revenue of $31.34 million for the quarter, compared to the consensus estimate of $28.69 million. Vericel had a negative return on equity of 7.58% and a negative net margin of 8.96%. The company's revenue for the quarter was up 34.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.01 earnings per share. View Vericel's Earnings History.
When is Vericel's next earnings date?
What guidance has Vericel issued on next quarter's earnings?
Vericel issued an update on its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $108-112 million, compared to the consensus revenue estimate of $109.9 million.
What price target have analysts set for VCEL?
4 brokers have issued twelve-month target prices for Vericel's shares. Their forecasts range from $17.92 to $23.00. On average, they anticipate Vericel's share price to reach $20.3067 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price. View Analyst Price Targets for Vericel.
What is the consensus analysts' recommendation for Vericel?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.
What are Wall Street analysts saying about Vericel stock?
Here are some recent quotes from research analysts about Vericel stock:
- 1. According to Zacks Investment Research, "Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. " (3/8/2019)
- 2. BTIG Research analysts commented, "$17 PT Heading into earnings, we viewed MACI’s ~23% Y/Y adjusted comp as achievable as the combo of increasing biopsy growth in YE17, rep additions, and low market penetration suggested another beatable Q. Viewed independent of the guidance raise, MACI’s 2Q18 result was in line with our Street-high expectations ($14.1M vs. BTIG’s $14.0M est.) but above Consensus ($13.7M) and while not bad, it may not excite investors looking for continued acceleration. That said, we do expect shares to be up tomorrow as guidance was raised ~9% (at the midpoint) to $80M – $83M (from $73M – $78M) as mgmt. sees strengthening momentum in 2H18 within MACI from biopsy strength, faster conversion times, new rep contributions, and continued marketing." (8/7/2018)
Has Vericel been receiving favorable news coverage?
Media headlines about VCEL stock have been trending positive on Saturday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Vericel earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the company's share price in the near term.
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include Repligen (RGEN), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Orchard Therapeutics (ORTX), Audentes Therapeutics (BOLD), Alector (ALEC), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA) and Editas Medicine (EDIT).
What other stocks do shareholders of Vericel own?
Who are Vericel's key executives?
Vericel's management team includes the folowing people:
- Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 55)
- Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)
- Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)
- Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
- Ms. Heidi Hassen, Sr. Director of HR
Who are Vericel's major shareholders?
Vericel's stock is owned by a number of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.04%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.
Which major investors are buying Vericel stock?
How do I buy shares of Vericel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel's stock price today?
One share of VCEL stock can currently be purchased for approximately $16.63.
How big of a company is Vericel?
Vericel has a market capitalization of $728.51 million and generates $90.86 million in revenue each year. The biotechnology company earns $-8,140,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Vericel employs 216 workers across the globe.
What is Vericel's official website?
How can I contact Vericel?
Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]
MarketBeat Community Rating for Vericel (NASDAQ VCEL)
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
